Livanova News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.11.19	LivaNova restrukturiert sein Geschäftsgebiet Herzklappen und beendet das Programm zum Austausch von Mitralklappen mit Caisson-Transkathetern (Businesswire)
20.11.19	LivaNova to Restructure its Heart Valve Business Line and End Caisson Transcatheter Mitral Valve Replacement Program (Businesswire)
19.11.19	LivaNova to Present at the Berenberg and Piper Jaffray Conferences (Businesswire)
01.11.19	LivaNova Honors Epilepsy Awareness Month (Businesswire)
24.10.19	LivaNova to Present at the Stifel 2019 Healthcare Conference (Businesswire)
23.10.19	Study Published in Neurology Shows Chronic Epilepsy Associated with Marker of Cardiac Electrical Instability (Businesswire)
03.10.19	LivaNova to Host Conference Call for Third Quarter 2019 Results (Businesswire)
27.09.19	LivaNova Enrolls First Patient in RECOVER Clinical Study (Businesswire)
13.09.19	LivaNova to Present Updates on Autonomic Regulation Therapy at the 23rd Annual Scientific Meeting of the Heart Failure Society of America (Businesswire)
06.09.19	LivaNova erhält die Zulassung der U.S. Centers for Medicare & Medicaid Services für die klinische RECOVER-Studie (Businesswire)
05.09.19	LivaNova Receives Approval from U.S. Centers for Medicare & Medicaid Services for RECOVER Clinical Study (Businesswire)
30.08.19	LivaNova präsentiert Erkenntnisse zur autonomen Regulationstherapie bei Herzinsuffizienz am Kongress der Europäischen Gesellschaft für Kardiologie 2019 (Businesswire)
30.08.19	LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2019 (Businesswire)
17.07.19	LivaNova bekämpft Beinischämie mit bahnbrechender bidirektionaler Kanüle (Businesswire)
16.07.19	LivaNova Combats Leg Ischemia with Breakthrough Bidirectional Cannula (Businesswire)
15.07.19	LivaNova Receives U.S. FDA 510(k) Clearance for LifeSPARC Advanced Circulatory Support System (Businesswire)
11.07.19	LivaNova feiert 25 Jahre Vagusnerv-Stimulationstherapie (Businesswire)
11.07.19	LivaNova Celebrates 25 Years of Vagus Nerve Stimulation Therapy (Businesswire)
19.06.19	LivaNova Welcomes Stacy Enxing Seng to Board of Directors (Businesswire)
17.06.19	LivaNova to Host Conference Call for Second Quarter 2019 Results (Businesswire)
23.05.19	LivaNova to Present at the Jefferies Healthcare Conference (Businesswire)
16.05.19	LivaNova to Present at the UBS Global Healthcare Conference (Businesswire)
03.05.19	New Data Emphasizing LivaNova Perceval Valve Durability to be Presented at the American Association for Thoracic Surgery Meeting (Businesswire)
01.05.19	LivaNova Reports First Quarter 2019 Results (Businesswire)
05.04.19	LivaNova Reports Preliminary Unaudited First Quarter 2019 Revenue Results (Businesswire)
01.04.19	LivaNova to Present at the Needham Healthcare Conference (Businesswire)
29.03.19	LivaNova Announces Settlement Agreement to Resolve Certain Litigation in the U.S. Related to the 3T Heater-Cooler Device (Businesswire)
18.03.19	LivaNova Announces Trui Hebbelinck as Chief Human Resources Officer (Businesswire)
15.03.19	LivaNova to Present Autonomic Regulation Therapy Findings for Chronic Heart Failure Patients at the American College of Cardiology 68th Annual Scientific Session (Businesswire)
25.02.19	LivaNova Announces Availability of Safety and Technical Information for Valve-in-Valve Procedures on Perceval Platform (Businesswire)
21.02.19	LivaNova’s Perceval Sutureless Aortic Heart Valve Receives National Reimbursement in Japan to Treat Patients with Aortic Valve Disease (Businesswire)
15.02.19	LivaNova Recognizes Final Decision from the U.S. Centers for Medicare & Medicaid Services Regarding National Coverage Determination for VNS Therapy for Treatment-Resistant Depression (Businesswire)
28.01.19	LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2018 Results (Businesswire)
17.01.19	New Studies in the U.S. and Europe Demonstrate LivaNova Perceval Valve’s Strong Performance and Economic Advantage in Aortic Disease Treatment (Businesswire)
26.11.18	LivaNova Partners with Greg Grunberg to Raise Epilepsy Awareness (Businesswire)
20.11.18	LivaNova Comments on Proposed Decision Memo from the U.S. Centers for Medicare & Medicaid Services Regarding National Coverage Determination for VNS Therapy for Treatment-Resistant Depression (Businesswire)
19.11.18	LivaNova to Present at the Piper Jaffray and Berenberg Conferences (Businesswire)
24.10.18	LivaNova to Present at the Stifel 2018 Healthcare Conference (Businesswire)
26.09.18	LivaNova to Host Conference Call for Third Quarter 2018 Results (Businesswire)
18.09.18	LivaNova Launches International Pivotal Study Evaluating Use of Autonomic Regulation Therapy for Heart Failure (Businesswire)
10.09.18	LivaNova Welcomes NICE Interventional Procedures Guidance on Sutureless Aortic Valve Replacement (Businesswire)
04.09.18	LivaNova VNS Therapy System for Drug-Resistant Epilepsy Could Save $77,000 Per Patient Over Five Years (Businesswire)
23.08.18	LivaNova Launches Global Clinical Registry to Assess VNS Therapy Treatment for Drug-Resistant Epilepsy Patients (Businesswire)
22.08.18	LivaNova to Present at Morgan Stanley Global Healthcare Conference (Businesswire)
06.08.18	LivaNova Concludes PRELUDE Study for Transcatheter Mitral Valve Replacement System (Businesswire)
03.07.18	LivaNova to Host Conference Call for Second Quarter 2018 Results (Businesswire)
14.06.18	LivaNova Receives FDA Clearance and Completes First Implant for its MEMO 4D Semi-rigid Mitral Annuloplasty Ring (Businesswire)
13.06.18	LivaNova Welcomes William Kozy to Board of Directors (Businesswire)
11.06.18	LivaNova’s Perceval Sutureless Aortic Heart Valve Approved in Japan (Businesswire)
01.06.18	NASH Data Drives MDGL To The Moon, VKTX Turns Head, FDA Nod For KTOV (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Livanova PLC

Aktien Top/Flop

Livanova Peer Group Nachrichten

Meistgelesene Nachrichten